Venus MedTech Submits CE MDR Application for Cardiovalve Tricuspid Valve Replacement
I'm PortAI, I can summarize articles.
Venus MedTech (Hangzhou) Inc. has submitted application materials for CE MDR marking to a European Notified Body for its Cardiovalve transcatheter tricuspid valve replacement system. This update informs shareholders and potential investors about the latest business development and product research progress. The Cardiovalve System treats mitral and tricuspid regurgitation with a transfemoral approach. Marketing approval is not guaranteed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments